Complement inhibitors for myasthenia gravis in adults
journal contribution
posted on 2025-10-14, 01:54 authored by Laura M White, Fiona J Clay, Anne-Marie ForbesAnne-Marie Forbes, Ryan Yann Shern Keh, James B Lilleker, Jennifer Spillane, Karen Storms, Jon Sussman, Katherine C DoddThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of complement inhibitors for treating myasthenia gravis in adults compared with control treatment (placebo or standard care).<p></p>
History
Related Materials
- 1.
Sub-type
- Article
Publication title
Cochrane Database of Systematic ReviewsMedium
ElectronicVolume
2025Issue
7Pagination
cd016098eISSN
1469-493XISSN
1361-6137Department/School
MusicPublication status
- Published online
Place of publication
EnglandEvent Venue
Lancaster Medical School, Lancaster University, Lancaster, UK.Rights statement
Copyright © 2025 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane CollaborationUsage metrics
Keywords
32 Biomedical and Clinical Sciences3211 Oncology and CarcinogenesisRare DiseasesMyasthenia GravisNeurosciencesClinical Trials and Supportive ActivitiesAutoimmune DiseaseClinical ResearchOrphan Drug6.1 PharmaceuticalsHumansComplement Inactivating AgentsAdultRandomized Controlled Trials as TopicAntibodies, Monoclonal, Humanized
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC